Skip to main content
Guei-Sheung Liu on Muck Rack

Guei-Sheung Liu

As seen in: Nature, Frontiers, The Conversation, Medical Xpress, BioRxiv, Genetic Literacy Project, Medicine Today
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Guei-Sheung

Contact Guei-Sheung, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Loss of ELF2 drives topotecan resistance in retinoblastoma revealed by genome-wide CRISPR-Cas9 screening - Cell Death & Disease

|
By Guei-Sheung Liu
| Nature Verified
Abstract The topoisomerase I inhibitor topotecan is an effective chemotherapeutic agent for retinoblastoma; however, treatment resistance remains a major clinical challenge, and its mechanisms remain elusive. Using genome-wide CRISPR-Cas9 knockout screening, we identified ELF2 as a key gene involved in topotecan resistance. Here, we show that surviving retinoblastoma cells exposed to topotecan showed progressively decreased ELF2 expression, accompanied by reduced apoptosis.
Open in Who Shared Issue with article?

Might CRISPR gene editing in medicine open up a can of 'unintended consequences' worms? RNA advances could address that threat

|
By Flora Hui, Guei-Sheung Liu
| Genetic Literacy Project
The United States Food and Drug Administration has approved the first-ever clinical trial that uses CRISPR-Cas13 RNA editing. Its aim is to treat an eye disease called wet age-related macular degeneration that causes vision loss in millions of older people worldwide. This trial marks a new frontier in gene therapy – the process of treating or curing medical conditions by changing a person’s genes. What makes it special is the fact the therapy targets RNA, instead of DNA.
Open in Who Shared Issue with article?

Might CRSPR gene editing in medicine open up a can of 'unintended consequences' worms? RNA advances could address that threat

|
By Flora Hui, Guei-Sheung Liu
| Genetic Literacy Project
The United States Food and Drug Administration has approved the first-ever clinical trial that uses CRISPR-Cas13 RNA editing. Its aim is to treat an eye disease called wet age-related macular degeneration that causes vision loss in millions of older people worldwide. This trial marks a new frontier in gene therapy – the process of treating or curing medical conditions by changing a person’s genes. What makes it special is the fact the therapy targets RNA, instead of DNA.
Open in Who Shared Issue with article?
See all 10 articles